What is the treatment for nephrotic syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Nephrotic Syndrome

The first-line treatment for nephrotic syndrome is corticosteroids, specifically prednisone, with second-line agents including cyclophosphamide, calcineurin inhibitors, or levamisole used for steroid-dependent or frequently relapsing cases. 1

Initial Corticosteroid Therapy

For First Presentation

  • Prednisone 60 mg/m²/day (maximum 60 mg) as a single daily dose for 4-6 weeks
  • Followed by 40 mg/m²/day (maximum 40 mg) on alternate days for 4-6 weeks
  • Total treatment duration: 8-12 weeks 1
  • For adults: Lower doses on a per kilogram basis (1 mg/kg/day for 8 weeks), with treatment duration extended to ≥16 weeks to improve remission rates 2

Response Assessment

  • In children: Remission typically occurs within 11 days
  • In adults: May take up to 16 weeks 3
  • Definition of remission: Negative or trace proteinuria for at least 3 consecutive days 1

Management of Relapses

Infrequent Relapses

  • Prednisone 60 mg/m²/day until remission for at least 3 days
  • Then alternate-day prednisone (40 mg/m²) for at least 4 weeks 1

Frequent Relapses (≥2 episodes within 6 months)

  • Daily prednisone until remission for at least 3 days
  • Then alternate-day prednisone for at least 3 months 1
  • Consider steroid-sparing agents due to risk of steroid toxicity 2

Second-Line Therapy for Steroid-Dependent or Frequently Relapsing Cases

Alkylating Agents

  • Cyclophosphamide: 2 mg/kg/day for 8-12 weeks (maximum cumulative dose 168 mg/kg) 2, 1
    • Induces long-term remissions in 25-70% of children 3
    • Keep total dose below 200 mg/kg to minimize gonadal toxicity 3
  • Chlorambucil: 0.1-0.2 mg/kg/day for 8 weeks (maximum cumulative dose 11.2 mg/kg) 2

Calcineurin Inhibitors

  • Cyclosporine: 3-5 mg/kg/day divided into 2 doses 2
    • Target trough levels: 50-100 ng/ml 1
    • Duration: 12-24 months 2, 1
    • Produces complete remissions in 85% of children and 79% of adults with steroid dependence 3
  • Tacrolimus: 0.1 mg/kg/day divided into 2 doses 1
    • Target trough levels: 5 ng/ml 1

Other Options

  • Levamisole: 2.5 mg/kg on alternate days for 12-24 months 2, 1
  • Mycophenolate mofetil: 600-1200 mg/m²/day divided into 2 doses for 6-24 months 1

Monitoring and Follow-up

During Treatment

  • Regular assessment of proteinuria
  • Monitor renal function
  • Blood pressure monitoring
  • Growth monitoring in children (height, weight)
  • Complete blood counts with alkylating agents or mycophenolate
  • Drug levels for calcineurin inhibitors 1

Infection Prevention

  • Pneumococcal and annual influenza vaccination
  • Defer live vaccines until prednisone dose is <1 mg/kg/day 1
  • Monitor for and promptly treat infections

Common Pitfalls and Complications

Treatment Pitfalls

  • Inadequate initial steroid duration
  • Rapid steroid tapering
  • Delayed introduction of steroid-sparing agents
  • Overlooking infections 1

Complications to Monitor

  • Short-term: Hypovolemia, acute kidney injury, infections, thrombosis
  • Long-term: Growth retardation, hypertension, cataracts, osteoporosis, diabetes 1
  • Steroid-specific: Cushingoid features, glucose intolerance, hip osteonecrosis (particularly in elderly and post-menopausal women) 2
  • Cyclophosphamide-specific: Bone marrow depression, hemorrhagic cystitis, hair loss, infertility 3

Special Considerations

Kidney Biopsy Indications

  • Late steroid resistance
  • Suspected secondary cause
  • Diagnosis before 1 year or after 12 years of age
  • Evaluation of nephrotoxicity due to calcineurin inhibitors 1

Treatment Goals

  • Reduction in proteinuria by at least 25% by 3 months
  • Reduction in proteinuria by 50% by 6 months 1
  • Target proteinuria of <0.5-0.7 g/24h by 12 months 1

The treatment approach should be adjusted based on response, with careful monitoring for side effects and complications of both the disease and its treatments.

References

Guideline

Nephrotic Syndrome Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pharmacological treatment of nephrotic syndrome.

Drugs of today (Barcelona, Spain : 1998), 1999

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.